ImaginAb Inc., an Inglewood biotech firm that develops molecular imaging for cancer immunotherapy, has raised nearly $8 million in capital, according to a recent Securities and Exchange Commission filing.

The document said the company sold nearly $7.7 million in shares to six investors.

A spokeswoman at the 10-year-old firm did not respond to a request for comment.

Its new cash infusion follows $38.8 million in venture capital raised by ImaginAb during three previous rounds since 2012. Major investors include France’s Merieux Developpement and Novartis Venture Fund of Switzerland.

The firm works to clinically manage cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.

Its proprietary imaging program for prostate cancer is in its second phase of clinical trials, according to ImaginAb’s website.

The company, which was co-founded by Anna M. Wu, named Martyn Coombs chief executive this spring.

Coombs, an industry veteran in nuclear medicine and imaging, previously served as president of DraxImage, where he reportedly tripled revenue in four years. He also held positions at Amersham (now GE Healthcare), Nihon Medi-Physics and Asterand.

– Dana Bartholomew